Last reviewed · How we verify
paclitaxel/anthracycline
Paclitaxel works by inhibiting cell division, while anthracyclines intercalate DNA strands to prevent cell replication.
Paclitaxel works by inhibiting cell division, while anthracyclines intercalate DNA strands to prevent cell replication. Used for Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | paclitaxel/anthracycline |
|---|---|
| Also known as | Alternative Non-cross-resistant Adjuvant Chemotherapy |
| Sponsor | Tao OUYANG |
| Drug class | Taxane and anthracycline |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel stabilizes microtubules, preventing their disassembly and thereby inhibiting cell division. Anthracyclines, on the other hand, intercalate DNA strands, which prevents the enzyme topoisomerase II from unwinding DNA, ultimately leading to cell death.
Approved indications
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (PHASE3)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
- Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (PHASE3)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paclitaxel/anthracycline CI brief — competitive landscape report
- paclitaxel/anthracycline updates RSS · CI watch RSS
- Tao OUYANG portfolio CI